Haleon Pakistan Begins Local Manufacturing of Panadol 500mg Tablets
Operations UpdateHaleon Pakistan Limited announced that it has commenced manufacturing Panadol 500mg tablets at its Jamshoro facility. The launch follows the company’s previously announced investment in the facility to produce its Panadol base portfolio and strengthen local manufacturing capacity. The tablets will feature a new beacon engraving design; the company says product quality and efficacy are unchanged.
Key Findings
- Manufacturing of Panadol 500mg tablets has commenced at Haleon Pakistan’s Jamshoro facility.
- The facility investment was previously announced on October 13, 2023, to produce the Panadol base portfolio and enhance production capacity.
- Locally manufactured tablets will have a beacon engraving instead of the existing “Panadol” text engraving.
- The company states the design change does not affect product quality or efficacy.
Disclosure Details
Entities Involved
Haleon Pakistan Limited, Panadol, Jamshoro manufacturing facility
Impact
Commencement of local production strengthens in-house manufacturing capabilities and supports reliable product availability in Pakistan.
⚡
Highlights summarize the key points from the company's official PSX filing. View the original filing for the complete details before making financial decisions.